Your browser doesn't support javascript.
loading
Effect of Baseline Resistance-Associated Substitutions on Thalassemia Patients with Chronic HCV Infection: A Two-Year Follow-Up.
Safarnezhad Tameshkel, Fahimeh; Karbalaie Niya, Mohammad Hadi; Khoonsari, Mahmoodreza; Ajdarkosh, Hossein; Faraji, Amir Hossein; Nikkhah, Mehdi; Motamed, Nima; Azarkeivan, Azita; Gholami, Ali; Sohrabi, Masood Reza; Keyvani, Hossein; Zamani, Farhad.
Afiliación
  • Safarnezhad Tameshkel F; Gastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Karbalaie Niya MH; Gastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Khoonsari M; Department of Virology, Iran University of Medical Sciences, Tehran, Iran.
  • Ajdarkosh H; Gastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Faraji AH; Gastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Nikkhah M; Gastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Motamed N; Gastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Azarkeivan A; Department of Social Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
  • Gholami A; Pediatric Hematology Oncology, Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Thalassemia Clinic, Tehran, Iran.
  • Sohrabi MR; Non-communicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran.
  • Keyvani H; Department of Epidemiology & Biostatistics, School of Public Health, Neyshabur University of Medical Sciences, Neyshabur, Iran.
  • Zamani F; Gastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, Iran.
Middle East J Dig Dis ; 13(1): 27-34, 2021 Jan.
Article en En | MEDLINE | ID: mdl-34712435
BACKGROUND Direct-acting antivirals (DAAs) against hepatitis C virus (HCV) infection showed the presence of resistant-associated substitutions (RASs). The aim of the present study was to carry out a follow-up of patients with baseline RASs to report the impact of RASs on DAA therapy outcome. METHODS In a cohort study, we analyzed NS5A and NS5B RASs among nine thalassemia cases by baseline RASs. In a 2-year follow-up, we analyzed viral markers and biochemical and hematological parameters of the participants and their sustained virologic response (SVR). Statistical analyses were performed using SPSS software version 22. RESULTS RASs for HCV subtype 1a included M28V, L31M, and H58P. For subtype 1b: L28M, R30Q, S24F, and C316N. And for subtype 3a: C316S, and S24F. In patients with cirrhosis (n = 5), ALT (p = 0.001) and AST (p = 0.007) levels were significantly reduced after treatment, and creatinine level slightly increased (p = 0.025). However, no significant data was observed in non-cirrhotic patients following the treatment. CONCLUSION The present study did not show any adverse effects of DAA therapy among patients with thalassemia suffering from chronic HCV infection with baseline RASs. Furthermore, reduction in ferritin and liver stiffness levels after DAA therapy could show the efficacy of DAA in such patients.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Risk_factors_studies Idioma: En Revista: Middle East J Dig Dis Año: 2021 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Irán
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Risk_factors_studies Idioma: En Revista: Middle East J Dig Dis Año: 2021 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Irán